PharmaRoth Labs Welcomes Two Respected Physicians to Board of Advisors
Results Of Sucanon® Clinical Trial to be Presented at the European Association For The Study of Diabetes Annual Meeting
LAS VEGAS, June 5, 2013 /PRNewswire/ — PharmaRoth Labs, Inc. (OTCPink: ROTH), the exclusive producer, marketer & distributor of Sucanon®, an oral Type-II Diabetes treatment, is pleased to introduce the two newest members of the Company’s Board of Advisors, Dr. Jose Alberto Rojas Jimenez and Dr. Alberto Meraz Soria. Dr. Rojas Jimenez recently concluded a clinical trial of Sucanon® on 98 Hispanic pre-diabetic patients, and the findings of the study are to be presented at the European Association for the Study of Diabetes Annual Meeting in Barcelona, Spain on September 23-27, 2013.
Dr. Rojas Jimenez is a graduate of the prestigious School of Medicine of the Autonomous University of San Luis Potosi. He is Board certified in Internal medicine. His affiliations and membership include: The American British Cowdray Medical Center, American College of Physicians, European Association for the Study of Diabetes, the American Diabetes Association and board member of the Morbi-mortality Health System Federal District. Dr. Rojas Jimenez is a pioneer in the area of ambulatory continuous glucose monitoring as a diagnostic tool in Mexico. He also belongs to the Speakers Bureau of Eli Lilly Mexico, AMK Health Care and P&G. As an expert in Diabetes, he has given over 350 presentations over the past 5 years.
Dr. Meraz Soria also graduated from the School of Medicine of San Luis Potosi, and he is Board Certified in Internal Medicine. Dr. Meraz Soria specialized in Critical Condition patients where he received honorific mention. He is affiliated with the Emergency Service Hospital Sante Fe and a deputy at ABC Pulmonary Physiology and Inhalotherapy Hospital. Dr. Meraz Soria also completed clinical course work thru the Clinical Diabetology Steno Group in Copenhagen, Denmark. Dr. Meraz Soria is coordinating the design and implementation of the new clinical trial that will start in the last quarter of this year.
“I am extremely proud to announce the addition of Drs. Rojas Jimenez and Meraz Soria to our Board of Advisors,” stated Luis Lopez, CEO of PharmaRoth. “Both men are highly renowned and have made significant contributions to the medical communities. In addition, Dr. Rojas Jimenez’s clinical trial with Sucanon® adds to the growing body of evidence that our product exceeds expectations not just in the stabilization of blood glucose, but also could be used as an alternative for metabolic syndrome that includes reduction in visceral body fat without any side-effects.”
Sucanon(®) is approved as an OTC treatment for Type-II diabetes by regulatory authorities in Mexico, containing natural ingredient. It is one of only three approved drugs in the multi-billion dollar market for a class of diabetic medications called “insulin sensitizers”. Pre-clinical and clinical studies conducted ex-US have shown that Sucanon(®) and other insulin sensitizers lower a patient’s blood sugar by increasing the muscle, fat and liver’s sensitivity to the body’s own naturally produced insulin.
For further information regarding Sucanon(®), please visit PharmaRoth Labs, Inc. website at http://pharmaroth.com/
About PharmaRoth Labs Inc.
PharmaRoth Labs, Inc. (ROTH) is focused on diabetes prevention and treatments. The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon(®), an oral treatment for Type-II diabetes. Sucanon(®) is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver’s sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars. PharmaRoth’s strategy is to increase awareness, acceptance, and distribution of Sucanon(®) globally.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company’s current plans and expectations, as well as future results of operations and financial condition. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact and Inquiries for Investor Relations:
Paramount Advisors, LLC
SOURCE PharmaRoth Labs, Inc.